AstraZeneca retires Medimmune name amid sales turnaround
Feb 14, 2019 · MedImmune, a biotech acquired by AstraZeneca in 2007, will cease to exist as an industry name as part of the pharma's restructuring efforts. The decision comes as …
MedImmune - Wikipedia
Under the contract with HHS, MedImmune will continue to make its seasonal FluMist vaccine and also develop a vaccine targeted specifically at the novel H1N1 virus. [5] MedImmune then won …
MedImmune Receives FDA Approval for Self-Administered Flu …
Sep 20, 2024 · AstraZeneca's MedImmune has received Food and Drug Administration approval for FluMist, an influenza vaccine that can be administered either by oneself or by a healthcare …
AZ forges surprise R&D deal with virus gene therapy biotech
5 days ago · MedImmune, the R&D arm of AstraZeneca has teamed up with California based 4DMT, a next-generation virus-based gene therapy research house developing a treatment for …
AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program …
MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ: AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ: INO) to terminate the DNA cancer vaccine development …
Medimmune'in(Licenses'cancer'immunotherapy'tremelimumab'from ... - Pfizer
Oct 3, 2011 · MedImmune, the global biologics arm of AstraZeneca, today announced execution of an in-licensing agreement with Pfizer Inc for tremelimumab (CP-675,206), a CTLA-4 …
MedImmune completes $500m acquisition of Amplimmune
Oct 8, 2013 · MedImmune, AstraZeneca's biologics arm, has bought Amplimmune, a US-based cancer immunology company, for up to $500 million. The deal adds multiple early-stage assets …
With $250M in Financing, AstraZeneca Spinout to Focus on Severe ...
Feb 28, 2018 · AstraZeneca has spun off six pipeline candidates being developed by its MedImmune subsidiary into a new company that said today it will be funded with $250 million …
AstraZeneca oncology portfolio strengthened as MedImmune
Oct 15, 2013 · AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired Spirogen, a privately-held biotech company focused on …
AstraZeneca spins out new biotech, shedding autoimmune drugs
Feb 28, 2018 · MedImmune Dive Brief: MedImmune, AstraZeneca plc's biologics R&D unit, will spin out six experimental drugs into a standalone biotech, aiming to speed development of …